- Home
- DOMH
as 04-23-2025 4:00pm EST
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 48.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 644.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | -2.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.83 - $13.58 | Next Earning Date: | 04-15-2025 |
| Revenue: | $18,146,000 | Revenue Growth: | 789.95% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Dominari Holdings Inc. News
DOMH Breaking Stock News: Dive into DOMH Ticker-Specific Updates for Smart Investing
TipRanks
5 days ago
Trump Trade: President said to end IRS Direct File, block DeepSeek
TipRanks
6 days ago
J Capital Research doubts American Data Centers will be good bet for investors
ACCESS Newswire
20 days ago
Dominari Holdings Highlights Supporting American Companies
The Wall Street Journal
23 days ago
The Trump Family Advances Its All-Out Crypto Blitz, This Time With Bitcoin Mining
CoinDesk
a month ago
A Public Company Boasting Trump's Sons on Advisory Board Is Buying BlackRock Bitcoin ETFs
CoinDesk
a month ago
A Public Company Boasting Trump's Sons on Advisory Board Is Buying BlackRock Bitcoin ETFs
PR Newswire
a month ago
Dominari Holdings Reports Preliminary FY 2024 Financial Results
Insider Monkey
a month ago
Why Dominari Holdings (DOMH) Skyrocketed on Monday?
Compare DOMH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DOMH Dominari Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.